Anti-metapneumovirus monoclonal antibody - MedImmune

Drug Profile

Anti-metapneumovirus monoclonal antibody - MedImmune

Alternative Names: Anti-hMPV MAb - MediImmune; mAb-338

Latest Information Update: 23 Sep 2009

Price : $50

At a glance

  • Originator ViroNovative
  • Developer MedImmune
  • Class Monoclonal antibodies; Viral vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Metapneumovirus infections

Most Recent Events

  • 15 Sep 2009 Pharmacodynamics data from a preclinical trial in human metapneumovirus presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
  • 18 Sep 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2007) added to the Viral Infections pharmacodynamics and immunogenicity sections
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top